Silver diamine fluoride (SDF) can stop tooth decay in young children when the topical liquid is brushed onto teeth, according to a large clinical trial funded by the National Institute of Dental and Craniofacial Research (NIDCR). The preliminary results, recently published in Pediatric Dentistry, show that 54% of cavities stopped progressing after SDF treatment, compared to 21% of those treated with a placebo.
NYU College of Dentistry was one of three clinical sites in the trial, which also included the University of Michigan and the University of Iowa. The overall study was led by Margherita Fontana, DDS, PhD, of the University of Michigan.
“The impact of this trial could be tremendous as it can offer us another tool in our toolkit for managing tooth decay in young children: a less invasive approach that can stop the progression of cavities without shots, drills, or fillings. We hope that access to this simple treatment could also help in reducing oral health disparities,” said Amr M. Moursi, DDS, PhD, professor and chair of the Department of Pediatric Dentistry and principal investigator at the NYU study site.
SDF is cleared by the Food and Drug Administration for treating dental sensitivity and is used off label to treat tooth decay, also known as cavities or dental caries. It can be easily and painlessly swabbed onto cavities and has been widely used for management of tooth decay in other countries for decades. Studies suggest that the silver in SDF kills cavity-causing microbes and helps stop destruction of the tooth, while the fluoride helps to rebuild and strengthen the tooth.
“Current treatments for severe early childhood caries rely on restoration and tooth extraction, which can involve general anesthesia,” said Dr. Fontana, the study’s lead investigator. “These interventions are expensive, cavities often return, and anesthesia can have long-term effects on a developing brain. We didn’t really have any other options until recently—SDF is a game changer.”
Researchers recruited children between the ages of 1 and 5 with severe tooth decay. An interim analysis of 599 children evaluated the proportion of cavities in which decay progression was stopped six months after a single treatment with SDF or a placebo.
Because the interim analysis revealed that SDF was effective in halting the progression of cavities, the trial was stopped early. Ending a trial early can allow particularly effective interventions to move toward FDA approval and become available to patients sooner. The team also reported no safety concerns with the treatment.
“SDF marketing authorization from FDA for treating dental cavities could lead to SDF becoming more widely available; more acceptable among providers, patients, and parents; and more likely to be covered by insurance,” said Dena Fischer, DDS, MSD, MS, director of NIDCR’s Center for Clinical Research and the Clinical Trials and Practice-Based Research Program. “Increasing patients’ access to caries treatment is essential for reaching children who are most in need.”
Researchers are now analyzing the final data from more than 800 children, including assessing SDF’s effects on tooth pain and quality of life, as well as potential side effects. Because SDF can darken the color of cavities, which may not be aesthetically pleasing, the researchers are also evaluating patient and parent satisfaction and acceptability.
“Oral health problems, such as untreated tooth decay, can have many public health impacts that affect both children and adults,” said NIDCR Director Rena D’Souza, DDS, PhD, MS. “This study provides evidence that SDF could be a powerful tool against cavities and help improve health and well-being of children.”
Tooth decay is the most common chronic disease of childhood, affecting nearly 46% of children in the United States, according to the Centers for Disease Control and Prevention. It disproportionately affects Hispanic and non-Hispanic Black children and children from lower-income households. Left untreated, cavities can put children at risk for chronic pain, impaired development, and long-term oral and overall health problems.
This research was supported by NIDCR grant UH3-DE027372.
Source: https://dental.nyu.edu/
News 30 April 2026
HuFriedyGroup, a global leader in dental instrument manufacturing, infection prevention, and education solutions, is proud to announce a new strategic partnership with Seattle Stud
News 28 April 2026
Study enrollment completion marks critical milestone in advancing bone regeneration for dental reconstruction using Theradaptive’s targeted therapeutic platform
News 27 April 2026
The American Association of Endodontists (AAE) is recognizing the publication of a new peer-reviewed study examining the impact of a longstanding collaboration
News 15 April 2026
Oryx Dental, the leader in clinically focused, cloud-based dental practice management software (DPMS), and Seattle Study Club, the nation’s top dental education network, recently announced a new...
USA 07 June 2026 - 30 November -0001
ICOI World Congress USA 2026: Event Preview and Professional Highlights
The ICOI World Congress USA 2026 will take place from August 13, 2026 to August 15, 2026 in TBD, USA, offering dental professionals a focused environment for continuing education, clinical updates...
Edra Professional Books 06 June 2026
Understanding Dental Insurance: A Practical Reference for Dental Professionals
Understanding Dental Insurance is an Edra professional dentistry reference focused on clinical practice, education and treatment planning.
New initiative invites dentists to experience DEXIS’ most advanced AI yet, built on scale, speed, and clinical trust.
News 05 June 2026
(Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/C
News 05 June 2026
(Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected Will